Parkinson DiseaseNCT04527809
Transcranial Direct Current Stimulation (tDCS) and Virtual Reality Task in Parkinson Disease
A study testing tDCS-active in people with Parkinson Disease, run by University of Sao Paulo at 1 site in Brazil.
Trial summary
A double-blinded randomized controlled trial will be conducted, and all the participants will undertake one session of non-immersive VR tasks and tDCS-active or tDCS-sham. It will be a cross-sectional protocol. All protocol will have the assessment of Autonomic Nervous System, through Heart Rate Variability Analysis. Read more about this study
- Who is it for?
- Ages 40 to 90 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- tDCS-active
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Jul 2019to 1 Nov 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Parkinson's Disease with diagnosis previoulsy confirmed by a specialized doctor.
- Agreement to participate in the research by signing the informed consent form.
Who cannot join
- Wheelchair use
- Unable to complete the procedures due to any reported fatigue.
- Unable to complete the procedures due having to leave previously.
- Could not stand without any kind of help, such as a carrier or walking aids.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
School of Arts, Sciences and Humanities of the University of Sao Paulo
São Paulo, São Paulo, 03828000
About this study
Official title: Effect of Transcranial Direct Current Stimulation (tDCS) on a Virtual Reality Task in Individuals With Parkinson's Disease - Cross-sectional Project
A double-blinded randomized controlled trial will be conducted, and all the participants will undertake one session of non-immersive VR tasks and tDCS-active or tDCS-sham. It will be a cross-sectional protocol. All protocol will have the assessment of Autonomic Nervous System, through Heart Rate Variability Analysis.
Read the detailed description
Study Design: A double-blinded randomized controlled trial will be conducted, and all the participants will undertake a non-immersive VR tasks and tDCS-active or tDCS-sham. It will be a cross-sectional protocol.
Participants and sampling: Participants will be recruited through referral by the coordinators of places or institutions who has patients available to participate in the state of São Paulo-Brazil.
Inclusion Criteria: Participants with idiopathic Parkinson's Disease, with diagnosis previously confirmed by a specialized doctor, will be included if they have the agreement to participate in the research by signing the informed consent form.
Exclusion Criteria: Participants will be excluded if they used a wheelchair, were unable to complete the procedures due to any reported fatigue or due to having to leave previously, and who could not stand without any kind of help, such as a carrier or walking aids.
Randomization Participants: Participants will be randomly allocated to either group 1 (tDCS-active and VR tasks) or group 2 (tDCS-sham and VR tasks). Randomization will be under the control of a blinded investigator who will be the only person allowed to manage the electronic security file of the randomization to assign the individuals. The investigator will be blind to the group in which the participant is allocated to.
Blinding: The participants, researchers and outcome assessors will remain blind throughout the study. To ensure proper blinding, the researcher responsible for that, will configurate the code of the tDCS device to sham or active before the proper application. It will be no difference between the devices for sham or active application of the tDCS, because the same device has these two options.
Allocation concealment: Allocation concealment will successfully be reached since no one involved in this study (i.e. the participants, researchers, and outcome assessors) will be aware of the treatment allocations.
Intervention
All participants will attend the assigned tDCS and VR intervention as follows: there will be one session of application of tDCS and non-immersive VR tasks during twenty minutes of intervention. The researchers will be trained to perform all interventions tDCS-sham, tDCS-active and VR tasks.
Virtual Reality intervention
During the application of the tDCS-active or sham, it will be performed tasks in non-immersive virtual reality environment to stimulate and verify the performance in the timing coincident task present in the software that will be used provided by the "Bridge Games". A software developed by the Research and Technological Applications in Rehabilitation (Grupo de Pesquisa e Aplicação Tecnológica em Reabilitação - PATER) group of the School of Arts, Sciences, and Humanities of the University of Sao Paulo (EACH-USP).
Heart Rate Variability (HRV): It will be analyzed the HRV when the participant is already in the tDCS-active or sham application + VR task. The HRV analysis will follow the guidelines of the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (TFESC \& NASPE, 1996). The strap (for data collection) will be positioned on the participant's chest, and the Polar RS800cx heart rate receiver will be positioned next to it. HRV will be recorded after the initial assessments at rest for 5 minutes, during virtual reality combined to tDCS training for 10 minutes and for rest after the intervention for 5 minutes, totalizing 20 minutes. For analysis of HRV data at rest 1000 consecutive RR intervals will be used and during the tasks 256 consecutive RR intervals will be used.
HR will be recorded beat by beat throughout the protocol by the Polar RS800CX FC Portable Monitor (Polar Electro, Finland) and RR intervals recorded by the monitor will be transferred to the Polar ProTreiner program (3.0 v., Polar Electro, Finland) , which allows HR visualization and cardiac period extraction in the "txt" file format.
Moderate digital filtering will be performed in the program itself complemented with manual filtering performed in Excel software to eliminate premature ectopic beats and artifacts, and only series with more than 95% sinus beats will be included in the study (Vanderlei et al., 2008).
HRV analysis will be performed using linear (time and frequency domain) and nonlinear methods that will be analyzed using Kubios HRV® software (Kubios HRV v.1.1 for Windows, Biomedical Signal Analysis Group, Department of Applied Physics, University of Kuopio, Finland).
tDCS Intervention
tDCS-active or tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. The device used will be the DS-Stimulator, from NeuroConn, which allows blindness of the subjects of the research and the experimenters.
Procedure: First, the demarcation and positioning of the tDCS device will be done, and the electrodes positioned at predetermined locations. Anodic TDCS with electrodes between 25-35 cm2, intensity of 2mA, density of up to 0.057 mA / cm2 for a period of 20 minutes will be used. However, for the TDCS-sham (placebo) the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
After five minutes of stimulation at rest, the individuals performed the VR training with the MoveHero game, first with the upper limbs (during 5 minutes), then with the lower limbs (5 minutes). The participants will have the rest of the time (5 minutes) (with tDCS (sham or active). After each session the participant will be questioned about the presence of adverse effects.
- Conditions
- Parkinson Disease
- Being tested
- tDCS-active, tDCS-sham
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tDCS-activeDevice
One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
tDCS-shamDevice
One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
| Study group | Role | What they receive |
|---|---|---|
| tDCS-active | Experimental | tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. Receives: Device: tDCS-active |
| tDCS-sham | Sham comparator | tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained. Receives: Device: tDCS-sham |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor skills improvement
The motor skills will be analyzed through the games developed specifically for analysis of motor skills, such as (interception skills, speed, accuracy and reaction time).
Measured: 8 weeks.
Secondary outcomes (1)
Heart Rate Variability
The HRV will be analyzed at rest (20 minutes), during active/sham-tDCS (20 minutes) and during recover from the intervention (10 minutes).
Measured: 8 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2020
- Study start1 Jul 2019
- Primary completion1 Mar 2020
- Study completion1 Nov 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The participants will undertake a single session of non-immersive VR tasks and tDCS-active or tDCS-sham.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Talita Dias da Silva, University of Sao Paulo
- Investigators
- Talita D Silva, Ph.D., Principal investigator, University of Sao Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04527809
- Sponsor's protocol ID
- 02908218.0.0000.5390
- Status last verified
- Aug 2020
- First submitted
- 2 Aug 2020
- Last updated
- 27 Aug 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Transcranial Direct Current Stimulation (tDCS) on a Virtual Reality Task in Individuals With Parkinson's Disease - Cross-sectional Project
- ClinicalTrials.gov ID
- NCT04527809
- Acronym / sponsor ID
- 02908218.0.0000.5390
- Conditions
- Parkinson Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 54 participants (actual)
- Lead sponsor
- University of Sao PauloUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 1 Mar 2020 (actual)
- Study completion
- 1 Nov 2020 (estimated)
- First posted
- 27 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A double-blinded randomized controlled trial will be conducted, and all the participants will undertake one session of non-immersive VR tasks and tDCS-active or tDCS-sham. It will be a cross-sectional protocol. All protocol will have the assessment of Autonomic Nervous System, through Heart Rate Variability Analysis.
Detailed description
Study Design: A double-blinded randomized controlled trial will be conducted, and all the participants will undertake a non-immersive VR tasks and tDCS-active or tDCS-sham. It will be a cross-sectional protocol.
Participants and sampling: Participants will be recruited through referral by the coordinators of places or institutions who has patients available to participate in the state of São Paulo-Brazil.
Inclusion Criteria: Participants with idiopathic Parkinson's Disease, with diagnosis previously confirmed by a specialized doctor, will be included if they have the agreement to participate in the research by signing the informed consent form.
Exclusion Criteria: Participants will be excluded if they used a wheelchair, were unable to complete the procedures due to any reported fatigue or due to having to leave previously, and who could not stand without any kind of help, such as a carrier or walking aids.
Randomization Participants: Participants will be randomly allocated to either group 1 (tDCS-active and VR tasks) or group 2 (tDCS-sham and VR tasks). Randomization will be under the control of a blinded investigator who will be the only person allowed to manage the electronic security file of the randomization to assign the individuals. The investigator will be blind to the group in which the participant is allocated to.
Blinding: The participants, researchers and outcome assessors will remain blind throughout the study. To ensure proper blinding, the researcher responsible for that, will configurate the code of the tDCS device to sham or active before the proper application. It will be no difference between the devices for sham or active application of the tDCS, because the same device has these two options.
Allocation concealment: Allocation concealment will successfully be reached since no one involved in this study (i.e. the participants, researchers, and outcome assessors) will be aware of the treatment allocations.
Intervention
All participants will attend the assigned tDCS and VR intervention as follows: there will be one session of application of tDCS and non-immersive VR tasks during twenty minutes of intervention. The researchers will be trained to perform all interventions tDCS-sham, tDCS-active and VR tasks.
Virtual Reality intervention
During the application of the tDCS-active or sham, it will be performed tasks in non-immersive virtual reality environment to stimulate and verify the performance in the timing coincident task present in the software that will be used provided by the "Bridge Games". A software developed by the Research and Technological Applications in Rehabilitation (Grupo de Pesquisa e Aplicação Tecnológica em Reabilitação - PATER) group of the School of Arts, Sciences, and Humanities of the University of Sao Paulo (EACH-USP).
Heart Rate Variability (HRV): It will be analyzed the HRV when the participant is already in the tDCS-active or sham application + VR task. The HRV analysis will follow the guidelines of the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (TFESC \& NASPE, 1996). The strap (for data collection) will be positioned on the participant's chest, and the Polar RS800cx heart rate receiver will be positioned next to it. HRV will be recorded after the initial assessments at rest for 5 minutes, during virtual reality combined to tDCS training for 10 minutes and for rest after the intervention for 5 minutes, totalizing 20 minutes. For analysis of HRV data at rest 1000 consecutive RR intervals will be used and during the tasks 256 consecutive RR intervals will be used.
HR will be recorded beat by beat throughout the protocol by the Polar RS800CX FC Portable Monitor (Polar Electro, Finland) and RR intervals recorded by the monitor will be transferred to the Polar ProTreiner program (3.0 v., Polar Electro, Finland) , which allows HR visualization and cardiac period extraction in the "txt" file format.
Moderate digital filtering will be performed in the program itself complemented with manual filtering performed in Excel software to eliminate premature ectopic beats and artifacts, and only series with more than 95% sinus beats will be included in the study (Vanderlei et al., 2008).
HRV analysis will be performed using linear (time and frequency domain) and nonlinear methods that will be analyzed using Kubios HRV® software (Kubios HRV v.1.1 for Windows, Biomedical Signal Analysis Group, Department of Applied Physics, University of Kuopio, Finland).
tDCS Intervention
tDCS-active or tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. The device used will be the DS-Stimulator, from NeuroConn, which allows blindness of the subjects of the research and the experimenters.
Procedure: First, the demarcation and positioning of the tDCS device will be done, and the electrodes positioned at predetermined locations. Anodic TDCS with electrodes between 25-35 cm2, intensity of 2mA, density of up to 0.057 mA / cm2 for a period of 20 minutes will be used. However, for the TDCS-sham (placebo) the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
After five minutes of stimulation at rest, the individuals performed the VR training with the MoveHero game, first with the upper limbs (during 5 minutes), then with the lower limbs (5 minutes). The participants will have the rest of the time (5 minutes) (with tDCS (sham or active). After each session the participant will be questioned about the presence of adverse effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- The participants will undertake a single session of non-immersive VR tasks and tDCS-active or tDCS-sham.
| Arm | Type | Receives |
|---|---|---|
| tDCS-active | Experimental | Device: tDCS-activetDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. |
| tDCS-sham | Sham comparator | Device: tDCS-shamtDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained. |
Who may qualify
- Ages
- 40 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Parkinson's Disease with diagnosis previoulsy confirmed by a specialized doctor.
- Agreement to participate in the research by signing the informed consent form.
Key exclusion criteria (4 listed)
- Wheelchair use
- Unable to complete the procedures due to any reported fatigue.
- Unable to complete the procedures due having to leave previously.
- Could not stand without any kind of help, such as a carrier or walking aids.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tDCS-activeOne session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task. | Device | tDCS-active |
| tDCS-shamOne session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task. | Device | tDCS-sham |
Primary outcome
Motor skills improvement
Time frame: 8 weeks.
The motor skills will be analyzed through the games developed specifically for analysis of motor skills, such as (interception skills, speed, accuracy and reaction time).
1 secondary outcome
Heart Rate Variability
Time frame: 8 weeks.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2020.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Parkinson Disease
RecruitingEarly Phase 1
[18F]ACI-15916 PET in α-synucleinopathies
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
Not yet recruitingPhase 4
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
Overactive Bladder, Parkinson Disease
RecruitingPhase 2
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
PARKINSON DISEASE (Disorder)
RecruitingObservational study
Parkinson's Disease in Type 1 Gaucher Disease
Parkinson Disease (PD), Type 1 Gaucher Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Talita D Silva, Ph.D. principal investigator
University of Sao Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing tDCS-active in people with Parkinson Disease, run by University of Sao Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor skills improvement (time frame: 8 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2020.